RU2004121177A - Применение прамипексола для лечения бокового амитрофического склероза - Google Patents

Применение прамипексола для лечения бокового амитрофического склероза Download PDF

Info

Publication number
RU2004121177A
RU2004121177A RU2004121177/14A RU2004121177A RU2004121177A RU 2004121177 A RU2004121177 A RU 2004121177A RU 2004121177/14 A RU2004121177/14 A RU 2004121177/14A RU 2004121177 A RU2004121177 A RU 2004121177A RU 2004121177 A RU2004121177 A RU 2004121177A
Authority
RU
Russia
Prior art keywords
pramipexole
tetrahydrobentiazole
treatment
alkyl
sclerosis
Prior art date
Application number
RU2004121177/14A
Other languages
English (en)
Inventor
Джеймс П. Мл. БЕННЕТТ (US)
Джеймс П. Мл. БЕННЕТТ
Original Assignee
Юниверсити Оф Вирджиния Пэйтент Фаундейшн (Us)
Юниверсити Оф Вирджиния Пэйтент Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Оф Вирджиния Пэйтент Фаундейшн (Us), Юниверсити Оф Вирджиния Пэйтент Фаундейшн filed Critical Юниверсити Оф Вирджиния Пэйтент Фаундейшн (Us)
Publication of RU2004121177A publication Critical patent/RU2004121177A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Artificial Filaments (AREA)
  • Noodles (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (10)

1. Способ лечения пациентов с ALS, включающий стадию введения указанному пациенту композиции, содержащей тетрагидробентиазол общей структуры
Figure 00000001
где R1, R2, R3 и R4 независимо выбраны из группы, включающей Н или С1-С3-алкил.
2. Способ по п.1, где R1, R2 и R4 представляют собой Н, а R3 представляет собой С1-С3-алкил.
3. Способ по п.1, где указанный тетрагидробентиазол представляет собой прамипексол.
4. Способ по п.3, где более 90% прамипексола в указанной композиции представляет собой R(+)-2-амино-4,5,6,7-тетрагидро-6-пропиламинобензатиазол.
5. Способ повышения биоэлектрического потенциала (ΔΨ) через митохондриальные мембраны клеток с нарушенной продукцией энергии в митохондриях, включающий стадию контакта указанных клеток с композицией, включающей тетрагидробентиазол общей структуры
Figure 00000002
где R1, R2, R3 и R4 независимо выбраны из группы, включающей Н или С1-С3-алкил.
6. Способ по п.5, где указанный тетрагидробентиазол представляет собой прамипексол.
7. Способ по п.6, где более 90% прамипексола представляет собой R(+)-2-амино-4,5,6,7-тетрагидро-6-пропиламинобензатиазол.
8. Способ снижения окислительного стресса у пациентов с ALS, включающий стадию введения указанному пациенту композиции, включающей тетрагидробентиазол общей структуры
Figure 00000003
где R1, R2 и R3 представляют собой Н, а R4 представляет собой С1-С3-алкил.
9. Способ по п.8, где указанный тетрагидробентиазол представляет собой прамипексол.
10. Способ по п.9, где указанный прамипексол представляет собой R(+)-2-амино-4,5,6,7-тетрагидро-6-пропиламинобензатиазол.
RU2004121177/14A 2001-12-11 2002-12-02 Применение прамипексола для лечения бокового амитрофического склероза RU2004121177A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33938301P 2001-12-11 2001-12-11
US60/339,383 2001-12-11
US34737102P 2002-01-11 2002-01-11
US60/347,371 2002-01-11

Publications (1)

Publication Number Publication Date
RU2004121177A true RU2004121177A (ru) 2005-03-10

Family

ID=26991607

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004121177/14A RU2004121177A (ru) 2001-12-11 2002-12-02 Применение прамипексола для лечения бокового амитрофического склероза

Country Status (20)

Country Link
US (4) US7157480B2 (ru)
EP (4) EP2246053B1 (ru)
JP (2) JP4500543B2 (ru)
KR (1) KR20040066890A (ru)
CN (1) CN1617720A (ru)
AT (1) ATE480235T1 (ru)
AU (1) AU2002360600B2 (ru)
CA (1) CA2468747C (ru)
CY (1) CY1111237T1 (ru)
DE (1) DE60237635D1 (ru)
DK (1) DK1453505T3 (ru)
ES (2) ES2432527T3 (ru)
HK (1) HK1150153A1 (ru)
HU (1) HUP0500001A3 (ru)
IL (1) IL162408A0 (ru)
MX (1) MXPA04005572A (ru)
PL (1) PL374310A1 (ru)
PT (1) PT1453505E (ru)
RU (1) RU2004121177A (ru)
WO (1) WO2003049705A2 (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE480235T1 (de) * 2001-12-11 2010-09-15 Univ Virginia Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
JP2009504748A (ja) * 2005-08-15 2009-02-05 ユニバーシティ オブ バージニア パテント ファウンデーション Ｒ（＋）プラミペキソールを用いた神経回復
WO2007045620A1 (de) * 2005-10-18 2007-04-26 Boehringer Ingelheim International Gmbh Verwendung von pramipexol zur behandlung des moderaten bis schweren restless legs syndroms (rls)
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
KR20090021169A (ko) * 2006-05-16 2009-02-27 크놉 뉴로사이언시스 인코포레이티드 Ｒ(+) 및 ｓ(-) 프라미펙솔을 포함하는 조성물 및 이의 사용 방법
EP2465500A1 (en) * 2006-05-16 2012-06-20 Knopp Neurosciences, Inc. Therapeutically effective amounts of R(+) and S(-) pramipexole for use in the treatment of parkinson's disease
AU2013209376B2 (en) * 2006-12-14 2016-05-05 Knopp Biosciences Llc Compositions and methods of using (r)-pramipexole
AU2016210640B2 (en) * 2006-12-14 2018-02-22 Knopp Biosciences Llc Compositions and methods of using (r)-pramipexole
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
CA2672596C (en) * 2006-12-14 2015-11-17 Michael E. Bozik Compositions and methods of using (r)-pramipexole
CA2680800A1 (en) * 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Modified release formulations of (6r)-4,5,6,7-tetrahydro-n6-propyl-2,6-benzothiazole-diamine and methods of using the same
WO2008113056A2 (en) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
GB0811642D0 (en) * 2008-06-25 2008-07-30 Univ Edinburgh Assay
EP2334185A4 (en) * 2008-08-19 2011-09-21 Knopp Neurosciences Inc COMPOSITIONS AND METHODS FOR USE OF (R) -PRAMIPEXOL
MX2011013577A (es) * 2009-06-19 2012-04-10 Knopp Neurosciences Inc Composiciones y metodos para tratar esclerosis lateral amiotrofica.
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
CA2921491C (en) 2012-08-23 2022-06-21 Susan Marie Metcalfe Neurotherapeutic nanoparticle compositions and devices
CA2885653A1 (en) * 2012-11-29 2014-06-05 Wayne State University Neuroprotective agents for treatment of neurodegenerative diseases
US10874669B2 (en) 2012-11-29 2020-12-29 Wayne State University Neuroprotective agents for treatment of neurodegenerative diseases
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
PL3019167T3 (pl) 2013-07-12 2021-06-14 Knopp Biosciences Llc Leczenie podwyższonych poziomów eozynofili i/lub bazofili
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
HUE055850T2 (hu) 2013-08-13 2022-01-28 Knopp Biosciences Llc Készítmények és módszerek a krónikus urticaria (csalánkiütés) kezelésére
CN111278425B (zh) 2017-09-11 2024-06-11 耶路撒冷希伯来大学伊萨姆研究开发有限公司 用于向脑部经鼻给药药物和用于全身作用的组合物和方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US560420A (en) 1896-05-19 Steam and oil separator
DE3447075A1 (de) * 1984-12-22 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
EP0186087B1 (de) 1984-12-22 1989-08-23 Dr. Karl Thomae GmbH Tetrahydro-benzthiazole, deren Herstellung und deren Verwendung als Zwischenprodukte oder als Arnzneimittel
DE3937271A1 (de) 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
US5650420A (en) * 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
US6156777A (en) 1994-12-15 2000-12-05 Pharmacia & Upjohn Company Use of pramipexole as a neuroprotective agent
JP3468526B2 (ja) * 1995-10-26 2003-11-17 サノフィーサンテラボ 筋萎縮性側索硬化症治療薬調製のための１−（２−ナフタ−２−イルエチル）−４−（３−トリフルオロメチルフェニル）−１，２，３，６−テトラヒドロピリジンの使用
GB9705428D0 (en) * 1997-03-15 1997-04-30 Knoll Ag Therapeutic agents
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
PE20000728A1 (es) * 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
DE19830201A1 (de) * 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
CA2301899C (en) * 1998-07-27 2008-11-18 Boehringer Ingelheim Pharma Kg Agent with an antidepressant activity
IL142896A0 (en) * 1998-11-02 2002-04-21 Elan Corp Plc Multiparticulate modified release composition
DE19938825A1 (de) 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Wirkstoffkombination mit Clonidin
AU7620600A (en) 1999-09-30 2001-04-30 General Hospital Corporation, The Use of pramipexole as a treatment for cocaine craving
PE20011074A1 (es) 2000-02-23 2001-10-04 Upjohn Co Uso de pramipexol en el tratamiento de trastornos de adiccion
WO2002004409A2 (en) * 2000-07-06 2002-01-17 Us Gov Health & Human Serv Tetrahydrobenzothiazole analogues as neuroprotective agents
DE10037619A1 (de) * 2000-08-02 2002-02-14 Daimler Chrysler Ag Anordnung von Bedienelementen
ES2187249B1 (es) * 2000-09-18 2004-09-16 Synthon Bv Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles.
WO2002028882A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism
DE10137082A1 (de) * 2001-07-28 2003-02-13 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
ATE480235T1 (de) * 2001-12-11 2010-09-15 Univ Virginia Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose
WO2003077902A1 (en) * 2002-02-19 2003-09-25 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
ES2359977T3 (es) * 2003-03-31 2011-05-30 Titan Pharmaceuticals, Inc. Dispositivo polimérico implantable para liberación sostenida de agonista de dopamina.
US7662987B2 (en) * 2003-07-15 2010-02-16 Xenoport, Inc. Methods for synthesis of acyloxyalkyl compounds
JP4971159B2 (ja) * 2004-08-13 2012-07-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング プラミペキソール又はその薬学的に許容しうる塩を含有する徐放性ペレット製剤、その製法及び使用
TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
JP2009504748A (ja) * 2005-08-15 2009-02-05 ユニバーシティ オブ バージニア パテント ファウンデーション Ｒ（＋）プラミペキソールを用いた神経回復

Also Published As

Publication number Publication date
IL162408A0 (en) 2005-11-20
US20050032856A1 (en) 2005-02-10
DK1453505T3 (da) 2010-11-15
CY1111237T1 (el) 2015-06-11
CN1617720A (zh) 2005-05-18
EP1453505B1 (en) 2010-09-08
JP2010031059A (ja) 2010-02-12
ATE480235T1 (de) 2010-09-15
US20130172394A1 (en) 2013-07-04
KR20040066890A (ko) 2004-07-27
US20070105918A1 (en) 2007-05-10
HUP0500001A3 (en) 2005-11-28
DE60237635D1 (de) 2010-10-21
CA2468747C (en) 2011-05-31
JP2005516911A (ja) 2005-06-09
MXPA04005572A (es) 2004-12-06
PT1453505E (pt) 2010-12-16
CA2468747A1 (en) 2003-06-19
AU2002360600B2 (en) 2007-11-29
EP1453505A4 (en) 2007-01-10
ES2432527T3 (es) 2013-12-04
PL374310A1 (en) 2005-10-03
US20110301210A1 (en) 2011-12-08
US7157480B2 (en) 2007-01-02
EP2246053A1 (en) 2010-11-03
EP1453505A2 (en) 2004-09-08
WO2003049705A3 (en) 2004-01-29
AU2002360600A1 (en) 2003-06-23
EP2305253A1 (en) 2011-04-06
HK1150153A1 (en) 2011-11-04
EP2246053B1 (en) 2013-09-18
WO2003049705A2 (en) 2003-06-19
ES2351303T3 (es) 2011-02-02
HUP0500001A2 (hu) 2005-04-28
EP2305252A1 (en) 2011-04-06
JP4500543B2 (ja) 2010-07-14

Similar Documents

Publication Publication Date Title
RU2004121177A (ru) Применение прамипексола для лечения бокового амитрофического склероза
ATE291433T1 (de) Extrakte von mutterkraut (tanacetum parthenium) gegen entzündliche erkrankungen
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
KR900013961A (ko) 기억력 및 학습력 증강 또는 인식 또는 정신장해 치료용 d-시클로세린 및 d-알라닌 함유 조성물
DE60113548D1 (de) Cyanomethyl-substituierte thiazolium- und imidazolium-verbindungen und behandlung von erkrankungen im zusammenhang mit proteinalterung
ATE487493T1 (de) Azolsäure-derivate, allein oder kombiniert, zur behandlung von diabetes und dyslipidaemien; und zur behandlung von malignen erkrankungen
DE69523350T2 (de) Behandlung von hyperproliferativen Gefässerkrankungen
PT734259E (pt) Utilizacao de derivados de piperidina para o tratamento da esquizofrenia
DE60137635D1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
DE60236639D1 (de) Neues verfahren und zusammensetzungen zur örtlichen behandlung von meniere-krankheit, tinnitus und/oder hörverlust
ATE45941T1 (de) Medizinische zusammensetzung zur behandlung von allergie-krankheiten.
DE69943107D1 (de) Behandlung von autoimmunerkrankungen
DE60237100D1 (de) Verwendung von leptin zur behandlung von lipoatropr prädisposition gegenüber der behandlung
DE60219614D1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
DE60203847D1 (de) Verbindungen enthaltend S-Tofisopam sowie Verwendung dieser Verbindungen zur Herstellung eines Medikamentes zur Behandlung oder Prophylaxe von Krämpfen und Anfällen
DK0994743T3 (da) Behandling af inflammatoriske lidelser i tarm eller urinblære
BRPI0211635B8 (pt) composto ciclo-hexil-sulfona, uso do mesmo, e, composição farmacêutica
DE69916632T2 (de) Verwendung von zimtsäurederivaten zur herstellung eines medikamentes zur vorbeugung oder behandlung von erkrankungen die durch einen hohen blutfettspiegel bedingt sind
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
ATE402257T1 (de) Antisense gegen c-myc zur behandlung von polyzystischer nierenkrankheit
PT83309A (de) Neue pyrrolo-benzimidazole pyrrolo-benzoxazole und pyrrolo-benzthiazole verfahren zu ihrer herstellung und diese verbindungen enthaltende arneimittel
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
BR9809673A (pt) Derivados de triptolida úteis no tratamento de doenças autoimunes
IT1245717B (it) Composto farmaceutico a base di un antocianidina per il trattamento di malattie oftalmiche

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20060110